keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg Clearance

keyword
https://www.readbyqxmd.com/read/28445927/vaccines-targeting-pres1-domain-overcome-immune-tolerance-in-hbv-carrier-mice
#1
Yingjie Bian, Zheng Zhang, Zhichen Sun, Juanjuan Zhao, Danming Zhu, Yang Wang, Sherry Fu, Jingya Guo, Longchao Liu, Lishan Su, Fu-Sheng Wang, Yang-Xin Fu, Hua Peng
Strong tolerance to HBV surface antigens limits the therapeutic effect of the conventional HBsAg vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen. To study whether targeting the weak tolerance of preS1 region could improve therapy gain, we explored vaccination with the long peptide of preS1 domain for HBV virions clearance. Our study showed that this preS1-polypeptide rather than HBsAg vaccination induced robust immune responses in the HBV carrier mice...
April 26, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28422873/clinical-features-of-treatment-naive-patients-with-hepatitis-b-virus-infection-a-community-based-survey-from-high-and-intermediate-hepatitis-b-endemicity-regions-in-southeast-china
#2
Wei Wu, Yu Zhu, Chenbo Yu, Shigui Yang, Bing Ruan, Yu Chen, Lanjuan Li
The aim of study was to investigate the clinical features of treatment-naive patients in 2 regions with high- and intermediate-hepatitis B endemicity level in Southeast China and provide the baseline data for monitoring health or planning therapy.This study included 8207 cases of treatment-naive patients with hepatitis B virus (HBV) infection from Yuhuan (YH, high-hepatitis B endemicity region) and Shaoxing (SX, intermediate-hepatitis B endemicity region) during 2014-2015. Clinical data were collected from the patients...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28407271/a-potent-hbsag-response-in-subjects-with-inactive-hbsag-carrier-treated-with-pegylated-interferon-alpha
#3
Zhenhuan Cao, Yali Liu, Lina Ma, Junfeng Lu, Yi Jin, Shan Ren, Zhimin He, Chengli Shen, Xinyue Chen
BACKGROUND: HBsAg clearance represents a clinical cure although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated-interferon α-2a (PEG-IFNα-2a) as a therapeutic option for inactive HBsAg carriers (IHCs). METHODS: 144 IHCs were enrolled and divided into a therapeutic group (102 subjects) and control group (42 subjects). PEG-IFNα-2a and PEG-IFNα-2a combined with Adefovir Dipivoxil (ADV) were used for treatment group subjects with hepatitis B virus (HBV) DNA <20 IU/mL and 20 IU/mL≤HBV DNA<2000 IU/mL, respectively...
April 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28404133/effect-on-hbs-antigen-clearance-of-addition-of-pegylated-interferon-alfa-2a-to-nucleos-t-ide-analogue-therapy-versus-nucleos-t-ide-analogue-therapy-alone-in-patients-with-hbe-antigen-negative-chronic-hepatitis-b-and-sustained-undetectable-plasma-hepatitis-b
#4
Marc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, Lawrence Serfaty, Patrick Marcellin, Yoann Barthe, Dominique Thabut, Dominique Guyader, Christophe Hezode, Magali Picon, Xavier Causse, Vincent Leroy, Jean Pierre Bronowicki, Patrizia Carrieri, Ghassan Riachi, Isabelle Rosa, Pierre Attali, Jean Michel Molina, Yannick Bacq, Albert Tran, Jean Didier Grangé, Fabien Zoulim, Hélène Fontaine, Laurent Alric, Inga Bertucci, Magali Bouvier-Alias, Fabrice Carrat
BACKGROUND: Findings from uncontrolled studies suggest that addition of pegylated interferon in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos(t)ide analogues with undetectable plasma hepatitis B virus (HBV) DNA might increase HBs antigen (HBsAg) clearance. We aimed to assess this strategy. METHODS: In this randomised, controlled, open-label trial, we enrolled patients aged 18-75 years with HBeAg-negative chronic hepatitis B and documented negative HBV DNA while on stable nucleos(t)ide analogue regimens for at least 1 year from 30 hepatology tertiary care wards in France...
March 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28387980/immune-balance-in-hepatitis-b-infection-present-and-future-therapies
#5
REVIEW
Ashish Kumar Vyas, Ankur Jindal, Syed Hissar, Gayatri Ramakrishna, Nirupama Trehanpati
Chronic hepatitis B virus (HBV) infection affects millions of people worldwide and about half a million people die every year. India represents the second largest pool of chronic HBV infections with an estimated 40 million chronically infected patients. Persistence or clearance of HBV infection mainly depends upon host immune responses. Chronically infected individuals remain in immune tolerant phase unless HBV flares and leads to development of chronic active hepatitis or acute on chronic liver failure. Strategies based on inhibition of viral replication (nucleoside analogues) or immune modulation (Interferons) as monotherapy, or in combination in sequential therapies, are currently being used globally for reducing HBV viral load and mediating HBsAg clearance...
April 7, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28376852/antiviral-efficacy-of-entecavir-for-hepatitis-b-virus-rta181v-t-mutants
#6
Ping Li, Jiabao Geng, Wei Li, Xiaobing Xu, Xin Zhang, Wenkai Zheng, Yuecheng Yu, Zhiguo Yang, Maorong Wang
BACKGROUND: The amino acid substitution at position 181 of the Hepatitis B virus (HBV) polymerase is a multi-drug resistance affecting both the L-nucleoside and acyclic phosphonate nucleotide groups. Data is limited on the efficacy of entecavir (ETV) rescuing chronic hepatitis B (CHB) patients with rtA181T/V mutation. METHODS: Thirty-one patients with rtA181T/V mutation and 25 patients with rtA181T/V and rtN236T mutation were enrolled. Virological, serological and biochemical outcomes of ETV rescue therapy over 12 months in CHB patients with rtA181T/V mutation strains were investigated...
April 4, 2017: Virology Journal
https://www.readbyqxmd.com/read/28325923/clinical-features-and-viral-quasispecies-characteristics-associated-with-infection-by-the-hepatitis-b-virus-g145r-immune-escape-mutant
#7
Yuan Xue, Ming-Jie Wang, Zhi-Tao Yang, De-Min Yu, Yue Han, Dao Huang, Dong-Hua Zhang, Xin-Xin Zhang
Coexistence of the hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is an uncommon phenomenon, and the underlying mechanisms remain largely unknown. Amino-acid (aa) substitution from glycine to arginine at aa 145 (G145R), in the major hydrophilic region, has been reported in patients with HBsAg and anti-HBs coexistence. However, there is limited knowledge about the clinical features and viral quasispecies characteristics associated with G145R mutant hepatitis B virus (HBV) infection...
March 22, 2017: Emerging Microbes & Infections
https://www.readbyqxmd.com/read/28321112/different-mechanisms-may-exist-for-hbsag-synthesis-and-secretion-during-various-phases-of-chronic-hepatitis-b-virus-infection
#8
Yunsong Li, Qun Cai, Qinxiu Xie, Yafei Zhang, Xiangling Meng, Zhenhua Zhang
BACKGROUND The aim of this study was to characterize the expression and secretion of hepatitis B surface-antigen (HBsAg) in the hepatocytes of hepatitis B virus (HBV)-infected patients at different phases of infection; as such, the association of intrahepatic HBsAg expression with virological markers and the histological characteristics were analyzed. MATERIAL AND METHODS 302 chronic HBV infection patients who had not received antiviral therapy were stratified by HBeAg status. The proportion of HBsAg-positive cells was used as an indicator for HBsAg expression level...
March 21, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28317872/preclinical-evaluation-of-the-efficacy-pharmacokinetics-and-immunogenicity-of-js-001-a-programmed-cell-death-protein-1-pd-1-monoclonal-antibody
#9
Jie Fu, Fang Wang, Li-Hou Dong, Jing Zhang, Cheng-Lian Deng, Xue-Li Wang, Xin-Yao Xie, Jing Zhang, Ruo-Xian Deng, Li-Bo Zhang, Hai Wu, Hui Feng, Bo Chen, Hai-Feng Song
JS-001 is the first monoclonal antibody (mAb) against programmed cell death protein-1 (PD-1) approved by the China Food and Drug Administration (CFDA) into the clinical trails. To date, however, no pre-clinical pharmacological and pharmacokinetic (PK) data are available. In this study, we investigated the efficacy of JS-001 and conducted a preclinical PK study, including the monitoring of anti-drug antibodies (ADAs). We found that JS-001 specifically bound to PD-1 antigen with an EC50 of 21 nmol/L, and competently blocked the binding of PD-1 antigen to PD-L1 and PD-L2 with IC50 of 3...
March 20, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28300730/the-enrichment-of-hbv-immune-escape-mutations-during-nucleoside-nucleotide-analogue-therapy
#10
Menglin Shan, Zhen Shen, Hua Sun, Jianghua Zheng, Min Zhang
BACKGROUND: Drug-resistant HBV mutants frequently arise during nucleos(t)ide analogues (NAs) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. Besides, the enrichment of immune-escape mutations was negatively correlated with HBsAg clearance under NAs therapy. This study aims to characterize the variability of hepatitis B virus polymerase and surface antigen in patients with virologic breakthrough under nucleos(t)ide analogues therapy...
March 16, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28296013/long-term-outcome-of-inactive-and-active-low-viraemic-hbeag-negative-hepatitis-b-virus-infection-benign-course-towards-hbsag-clearance
#11
Filippo Oliveri, Lidia Surace, Daniela Cavallone, Piero Colombatto, Gabriele Ricco, Nicola Salvati, Barbara Coco, Veronica Romagnoli, Riccardo Gattai, Antonio Salvati, Francesco Moriconi, Quan Yuan, Ferruccio Bonino, Maurizia R Brunetto
BACKGROUND & AIMS: The difference between the long-term outcome of low-viraemic (HBV-DNA≤20 000-IU/mL, LV-AC) and inactive HBsAg carriers (HBV-DNA≤2000-IU/mL, IC) remains to be defined. We studied prospectively 153 HBeAg-negative HBsAg-carriers with baseline HBV-DNA≤20 000-IU/mL and normal transaminases. METHODS: IC, LV-AC or chronic hepatitis B (CHB) (HBV-DNA persistently ≤2000-IU/mL, ≤20 000-IU/mL or >20 000-IU/mL respectively) were diagnosed after 1-year, 3-monthly monitoring...
March 13, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28291736/association-of-vitamin-d-related-genetic-variations-and-treatment-response-to-pegylated-interferon-in-patients-with-chronic-hepatitis-b
#12
Umaporn Limothai, Natthaya Chuaypen, Apichaya Khlaiphuengsin, Salyavit Chittmittraprap, Yong Poovorawan, Pisit Tangkijvanich
BACKGROUND: Vitamin D, a potent immune-modulator, has been linked to the pathogenesis of chronic hepatitis B (CHB). This study was aimed at investigating the association between single nucleotide polymorphisms (SNPs) in vitamin D-related genes and treatment response to pegylated interferon (PEG-IFN) in patients with CHB. METHODS: A total 275 Thai patients (122 HBeAg-positive and 153 HBeAg-negative CHB) treated with 48-week PEG-IFN were recruited. Virological response (VR) at 48 weeks post treatment was defined as HBeAg seroconversion plus HBV DNA <2,000 IU/mL for HBeAg-positive CHB and HBV DNA <2,000 IU/mL for HBeAg-negative CHB...
March 14, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28252163/a-large-scale-analysis-study-on-the-clinical-and-viral-characteristics-of-hepatitis-b-infection-with-concurrence-of-hepatitis-b-surface-or-e-antigens-and-their-corresponding-antibodies
#13
Y Xiang, P Chen, J R Xia, L P Zhang
Concurrent detection of hepatitis B surface antigen (HBsAg) and anti-HBs antibody or hepatitis B surface E antigen (HBeAg) and anti-HBe antibody in patients with chronic hepatitis B (CHB) infection is well established. However, the clinical implications of these proteins remain largely unknown. In this study, demographic, clinical, and laboratory data from 124,865 patients with chronic CHB infection were analyzed. Viral genotypes were determined by nested polymerase chain reaction. A chemiluminescent assay was applied to measure HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in sera...
February 23, 2017: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/28240596/discontinuation-of-lamivudine-treatment-in-hbeag-negative-chronic-hepatitis-b-a-pilot-study-with-long-term-follow-up
#14
Fatih Karakaya, Sevil Özer, Çağdaş Kalkan, E Ali Tüzün, Aysun Çalışkan, Onur Keskin, Gökhan Kabaçam, Senem Karatayli, Ersin Karatayli, A Mithat Bozdayi, Ramazan Idilman, Cihan Yurdaydin
BACKGROUND: Finite treatment of HBeAg-negative chronic hepatitis B (CHB) with nucleos(t)ide analogs (NAs) is important in resource limited countries. Outcome of treatment discontinuation in patients on long-term lamivudine (LVD) was assessed in a single center observational pilot study in the current study. METHODS: Non-cirrhotic patients on LVD for at least 5 years with undetectable HBV DNA on at least two consecutive assessments were offered to stop treatment...
February 27, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28207518/virological-and-serological-features-of-acute-hepatitis-b-in-adults
#15
Xiaofei Du, Yali Liu, Lina Ma, Junfeng Lu, Yi Jin, Shan Ren, Zhimin He, Xinyue Chen
Various viral kinetics among patients with acute hepatitis B (AHB) have been observed in clinical practice. This study investigated the virological, biochemical, and serological characteristics of AHB in adults.A total of 192 adult patients with AHB were recruited between December 2010 and January 2014. The quantification of biochemical and serologic markers for hepatitis B virus (HBV) infection was monitored from the onset.Of the 192 patients, 113 patients were followed up. One patient died due to acute liver failure, 2 developed chronic HBV infection...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28121714/hepatitis-delta-and-hiv-infection
#16
Vincent Soriano, Kenneth E Sherman, Pablo Barreiro
Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Although cure of hepatitis C and control of hepatitis B with antivirals avert liver disease progression in most HIV-coinfected patients, the lack of satisfactory treatment for hepatitis delta virus (HDV) infection remains a major threat for developing cirrhosis and liver cancer in this population. In the European Union (EU) and North America, sexual contact has replaced injection drug use that has been the major transmission route for HDV in HIV-positive persons...
April 24, 2017: AIDS
https://www.readbyqxmd.com/read/28092214/treatment-of-delta-hepatitis-today-and-in-the-future-a-review
#17
REVIEW
Ibrahim Halil Bahcecioglu, Abdurrahman Sahin
Hepatitis delta virus (HDV) is a defective satellite virus and propagates in the presence of Hepatitis B virus (HBV) surface antigen (HBsAg). Approximately 5% of the people who infected with HBV are also infected with HDV. Chronic hepatitis caused by delta is the most severe form of chronic viral hepatitis including accelerated fibrosis, liver decompensation and development of hepatocellular carcinoma. Interferon-based therapies still remain the only treatment option of the hepatitis delta. The beneficiary effects of the interferon-based therapies, however, stop frequently with termination of the given therapy and relapse rate is very high...
April 2017: Infectious Diseases
https://www.readbyqxmd.com/read/28073409/-a-study-of-immune-response-to-hbsag-mediated-by-cd4-memory-t-lymphocytes-in-immunized-hbv-transgenic-mice
#18
Y Li, J H Chen, X G Shu, J H Chen, Q H Xia, W Z Yuan, L Wu, Q Tang, G B Wang
Objective: To investigate the mechanism of immune response to HBsAg mediated by CD4+ memory T lymphocytes in immunized HBV transgenic (Tg) mice. Methods: Peripheral CD4+ memory T lymphocytes were isolated and collected by magnetic bead sorting from C57BL/6 mice successfully immunized by hepatitis B vaccine. Adoptive immunization was performed for Tg mice by caudal vein injection, and the peripheral blood was collected at 4 and 8 weeks after adoptive immunization. Enzyme-linked immunosorbent assay was used to measure the levels of HBsAg, anti-HBs, interferon-γ (IFNγ), and interleukin-2 (IL-2), and immunohistochemistry was used to measure the level of HBsAg in the liver...
December 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28056752/inhibiting-the-secretion-of-hepatitis-b-surface-antigen-hbsag-to-treat-hepatitis-b-infection-a-review
#19
Simon D Baugh
Chronic Hepatitis B is a major global health issue, and has no known cure. Currently there are over 240 million people infected with the disease, and it leads to the death of over 686,000 people each year. A total of seven treatments which help to control the disease are currently available: interferon-based treatments (pegasys, and interferon alpha), and nucleoside and nucleotide analogs (Viread, Baraclude, Tyzeka, Hepsera, Epivir-HBV), but all require continuing treatment to maintain control of the disease...
January 4, 2017: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/28052637/future-anti-hbv-strategies
#20
REVIEW
Edward J Gane
Although current oral antivirals can maintain viral suppression and reduce the risk of liver-related complications, lifelong therapy is associated with high cost, risk of breakthrough and potential toxicity. There is a need to develop a finite course of treatment which can provide sustained off-treatment virological and clinical response. The likely marker of such a clinical HBV CURE would be HBsAg clearance, but in addition cccDNA elimination would be required to prevent future reactivation (ie complete HBV cure)...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
42773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"